Roivant Cuts Multiple R&D Programs As It Takes On Pfizer’s TYK2/JAK1 Inhibitor

Sickle Cell, Dermatology And Cancer Drugs Among Discontinued Assets

 
• By Mandy Jackson
  
Digital money send, currency exchange sign. Neon futuristic transfer arrow icon. Web trade symbol. Mutual exchange of information isolated on blue background
Roivant swapped out multiple programs to conserve cash and bring in a late-stage Pfizer asset • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business